Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker

HC Wainwright initiated coverage on Gyre Therapeutics (GYRE) with a Buy rating and an $18 price target, citing significant upside potential from its fibrosis-focused pipeline, particularly the lead asset hydronidone. Despite a Q2 sales miss, the analyst projects hydronidone could achieve $6 billion in annual U.S. sales by 2033, following positive Phase 3 results for liver fibrosis in China and planned U.S. Phase 2 trials for MASH. This bullish outlook positions Gyre as a compelling, under-the-radar opportunity in the evolving biopharmaceutical landscape, despite the stock's recent decline.

Analysis

HC Wainwright has initiated coverage on Gyre Therapeutics with a 'Buy' rating and an $18 price target, signaling substantial upside from its current price of $7.70. The bullish thesis is primarily centered on the blockbuster potential of its lead asset, hydronidone, which the analyst projects could reach $6 billion in annual U.S. sales by 2033. This forecast is supported by hydronidone's successful Phase 3 trial in China for liver fibrosis, where it met its primary endpoint with high statistical significance (P=0.0002), and its planned entry into U.S. Phase 2 trials for MASH in H2 2025. The analyst draws a parallel to the success of Madrigal's Rezdiffra, suggesting a large, validated market opportunity. However, this long-term potential contrasts with Gyre's current financial performance. The company missed Q2 sales consensus with $26.78 million versus an expected $30.8 million, and its full-year 2025 revenue guidance of $118-$128 million represents modest growth. The stock's 6.04% decline on the day of the positive initiation, trading below its recent $9.00 public offering price, indicates that investors remain skeptical and that the company's story, as the analyst notes, is 'flying under the radar' pending further clinical and commercial de-risking.

Key Decisions for Investors

• Given the significant disparity between the current stock price of $7.70 and the analyst's $18 target, risk-tolerant investors could view the current valuation as an attractive entry point for a long-term, catalyst-driven investment in the company's fibrosis pipeline.
• Investors should closely monitor the company's ability to meet its 2025 revenue guidance of $118-$128 million, as the recent Q2 sales miss highlights execution risk in its existing commercial portfolio while the key pipeline assets mature.
• The primary catalysts to watch are the planned Q3 2025 New Drug Application submission for hydronidone in China and the initiation of its U.S. Phase 2 trial in H2 2025, as progress on these fronts is essential to de-risking the asset and validating the analyst's bullish thesis.